Back to Search
Start Over
Post-treatment with oxcarbazepine confers potent neuroprotection against transient global cerebral ischemic injury by activating Nrf2 defense pathway.
- Source :
-
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2020 Apr; Vol. 124, pp. 109850. Date of Electronic Publication: 2020 Jan 22. - Publication Year :
- 2020
-
Abstract
- Oxcarbazepine (OXC), a voltage-gated sodium channel blocker, is an antiepileptic medication and used for the bipolar disorders treatment. Some voltage-gated sodium channel blockers have been demonstrated to display strong neuroprotective properties in models of cerebral ischemia. However, neuroprotective effects and mechanisms of OXC have not yet been reported. Here, we investigated the protective effect of OXC and its mechanisms in the cornu ammonis 1 subfield (CA1) of gerbils subjected to 5 min of transient global cerebral ischemia (tGCI). tGCI led to death of most pyramidal neurons in CA1 at 5 days after ischemia. OXC (100 and 200 mg/kg) was intraperitoneally administered once at 30 min after tGCI. Treatment with 200 mg/kg, not 100 mg/kg OXC, significantly protected CA1 pyramidal neurons from tGCI-induced injury. OXC treatment significantly decreased superoxide anion production, 4-hydroxy-2-nonenal and 8-hydroxyguanine levels in ischemic CA1 pyramidal neurons. In addition, the treatment restored levels of superoxide dismutases, catalase, and glutathione peroxidase. Furthermore, the treatment distinctly inhibited tGCI-induced microglia activation and significantly reduced levels of pro-inflammatory cytokines (interleukin-1β and tumor necrosis factor-α). In particular, OXC treatment significantly enhanced expressions of nuclear factor erythroid 2-related factor 2 (Nrf2) and its downstream protein heme oxygenase-1 in ischemic CA1. The neuroprotective effects of OXC were abolished by brusatol (an inhibitor of Nrf2). Taken together, these results indicate that post-treatment of OXC can display neuroprotection against brain injuries following ischemic insults. This neuroprotection may be displayed by attenuation of oxidative stress and neuroinflammation, which can be mediated by activation of Nrf2 pathway.<br />Competing Interests: Declaration of Competing Interest The all authors declare that there are no conflicts of interest.<br /> (Copyright © 2020 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.)
- Subjects :
- Animals
Brain Ischemia physiopathology
CA1 Region, Hippocampal drug effects
CA1 Region, Hippocampal pathology
Catalase metabolism
Cytokines metabolism
Dose-Response Relationship, Drug
Gerbillinae
Glutathione Peroxidase metabolism
Inflammation Mediators metabolism
Male
Neuroprotective Agents administration & dosage
Oxcarbazepine administration & dosage
Oxidative Stress drug effects
Pyramidal Cells drug effects
Superoxide Dismutase metabolism
Voltage-Gated Sodium Channel Blockers administration & dosage
Voltage-Gated Sodium Channel Blockers pharmacology
Brain Ischemia drug therapy
NF-E2-Related Factor 2 metabolism
Neuroprotective Agents pharmacology
Oxcarbazepine pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 1950-6007
- Volume :
- 124
- Database :
- MEDLINE
- Journal :
- Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
- Publication Type :
- Academic Journal
- Accession number :
- 31981945
- Full Text :
- https://doi.org/10.1016/j.biopha.2020.109850